sample="quota" bates="500905619" isource="rjr" decade="1980" class="ui" date="19840618" Proposed Procedures for Managing and Monitoring Research Projects The Project 1. Fit with our objective 2. Purpose 3. Importance 4. Need 5. Duration 6. Results Measurement The Leader 1. Track record The Institution 1. Record of support 2. Adequacy of facilities 3. Management 4. Tax exemption The Cost 1. Budget 2. Fiscal responsibility 3. Accountability 4. Audit Other Support 1. Who supports 2. Plans for when ours stops Proposed Procedures for Managing and Monitoring Research Projects The Project 1. Fit with our objectives 2. Purpose 3. Importance 4. Need 5. Duration 6. Results measurement The Leader 1. Track record The Institution 1. Record of support 2. Adequacy of facilities 3. Management 4. Tax exemption The Cost 1. Budget 2, Fiscal responsibility 3. Accountability 4. Audit Other Support 1. Who supports 2. Plans for when our stops MEDICAL RESEARCH ADVISORY COMMITTEE (MRAC) INTRODUCTION Thirty years ago, about ten years prior to the 1964 Surgeon General's Report, R. J. Reynolds Tobacco Company began its involvement with biomedical research. From that beginning there have emerged four distinct directions. 1. The first of these is industry-supported research begun through what is now known as the Council for Tobacco Research (CTR). That continues to represent the industry-sponsored approach into research related directly to smoking and health. R.J. Reynolds Tobacco Company is the largest single supporter of research through CTR. 2. In 1976 R.J. Reynolds Industries began a program of support for basic biomedical research, the objectives of which were: a. to discharge an obligation of corporate citizenship, b. to establish credibility in the scientific community, and c. to contribute to the prevention and cure of diseases for which tobacco products have been associated. 3. In 1983, R. J. Reynolds Tobacco Company initiated a program of support for research in the biomedical sciences, specifically concentrating on the processes of the various chronic degenerative diseases with which tobacco is associated. 4. Also in 1983 R. J. Reynolds Tobacco Company's R&D function initiated a program of research designed to study the characteristics and scope of the defense mechanisms of the "normal" lung. Except for items 1 and 4, research into chronic degenerative disease has been coordinated by the Contributions Committee of the Board of Directors of R. J. Reynolds Industries, Inc. Separate advisory committees however have been created to administer the medical research initiated by R. J. Reynolds Tobacco Company in 1983 and that begun by R. J. Reynolds Industries in 1976. It is the purpose of this committee to bring numbers 2 & 3 together so that three distinct programs will result: 1. That managed by the Council for Tobacco Research, which is partially financed by R. J. Reynolds Tobacco Company. 2. That managed by R&D function of R. J. Reynolds Tobacco Company and dealing with product related research; and 3. That managed by the Contributions Committee of the Board of Directors of R. J. Reynolds Industries, Inc. It is the third of these items with which this paper is concerned. CONSTITUTION OF THE COMMITTEE In the interest of promoting coordination of medical research, a committee has been formed consisting of the Senior Vice President, Corporate Research and Development, of R. J. Reynolds Industries, the Vice President, Research and Development, of R. J. Reynolds Tobacco Company, the Senior Vice President, General Counsel and Secretary of R. J. Reynolds Industries and the Vice President, General Counsel and Secretary of R. J. Reynolds Tobacco Company. The committee is chaired by the Senior Vice President, Corporate Research and Development of R. J. Reynolds Industries, Inc. PURPOSE OF COMMITTEE The general purpose of the Medical Research Advisory Committee (MRAC) is to act in an advisory capacity to the Contributions Committee of the Board of Directors of R. J. Reynolds Industries, Inc. Members of MRAC will be expected to both initiate recommendations of support for projects meeting corporate objectives and to accept responsibility for monitoring and evaluating grants made to major selected grantees. More specifically, but without limitation, MRAC's advisory responsibilities will include: . reviewing from time to time the Company's policies and objectives in regard to medical research and recommending changes therein as seem advisable; 2. reviewing and suggesting appropriate changes in proposed budgets for medical research before submission to the Contributions Committee of the Board of Directors; 3. researching and evaluating specific requests and recommending disposition thereof to the Contributions Committee of the Board of Directors; and 4. overseeing the ongoing research projects which are under the purview of the Contributions Committee to assure adherence to research grants. APPOINTMENTS AND TERM OF OFFICE All appointments will be made by the Chairman of the Contributions Committee of the Board of Directors of R. J. Reynolds Industries, Inc. Appointments will be made in April of each year and shall be for one year beginning May 1. VACANCIES An appointee shall cease to be a member of the Committee if his employment terminates or if he is transferred to another operation of the Company. A replacement shall be appointed by the Chairman of the Contributions Committee of the Board of Directors to fill the unexpired term created by the vacancy. QUORUM A majority of the members shall constitute a quorum, whether at a called meeting or without a meeting being held. MEETINGS MRAC shall meet at such times and places as its Chairman may specify. EXPENSES Meeting expenses, excluding travel and lodging of participants employed by the Company or one of its operating units, and expenses for consultancy fees shall be paid from a budget to be established by MRAC and administered by its Chairman. OFFICERS There shall be a Chairman and a Secretary. The Chairman shall be appointed by the Chairman of the Contributions Committee of the Board of Directors. The Secretary shall be the Director of Corporate Contributions of the Company.